Press Releases Valneva

Equities

VLA

FR0004056851

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:55:00 16/01/2026 GMT			5-day change	1st Jan Change
4.388 ^EUR	+2.81%		+3.10%	+18.02%

01-06	Valneva Surges on Positive Broker Comments
01-06	Stifel Raises Price Target for Valneva

Press Releases

01-12	Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference	AQ
01-09	Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference	GL
12-31	Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement	GL
12-10	Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®	GL
11-26	Valneva to Further Consolidate its Operations in France	GL
11-26	Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate	GL
11-20	Valneva : 9M 2025 Financial Results	PU
11-20	Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates	GL
11-19	Valneva : Nine-month 2025 Financial Results	PU
11-04	Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate	GL
27/10/25	Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences	GL
06/10/25	Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates	GL
30/09/25	Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®	GL
03/09/25	Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate	GL
25/08/25	Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.	GL
25/08/25	Valneva : Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® In the U.S.	PU
18/08/25	Valneva's Chikungunya Vaccine IXCHIQ Now Authorized in Canada for Individuals Aged 12 and Older	AQ
18/08/25	Valneva : Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus	PU
18/08/25	Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older	GL
18/08/25	Valneva : Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older	PU
12/08/25	Valneva : H1 2025 Financial Results	PU
12/08/25	Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates	GL
07/08/25	Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information	GL
11/07/25	Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly	GL
26/06/25	Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Valneva: the return of biotech euphoria?

August 13, 2025 at 08:07 am